Mental health and precision medicine

QUEBEC, September 22, 2022 /CNW Telbec/ – The only known company in the world that captures retinal signals and decodes their specific biosignatures schizophrenia (SZ), Bipolar Disorder (BP) and depression (MDD), diaMentis intends to offer its rapid diagnostic support technology to general practitioners and psychiatrists in Germany The United States and Canada until the end of 2024.

New technology to quickly help mental health patients and doctors

Of all medical disciplines, psychiatry is the only one without an objective tool for diagnosing and monitoring patients undergoing treatment. Once approved, this new technology could transform the lives of millions of people thanks to an approximately 45-minute electroretinography (ERG) test, further analyzed by diaMentis’ patented SaMD (Software as a Medical Device) platform. It should be noted that in The United States ¹more than 29 million adults suffer from one of these diseases, while in Canadamore than 2.3 million people aged 15 and over are affected ².

The only known company in the world, the one breakthrough designation (Significant Scientific Advances) from the American Agency related to biosignature analysis and diagnostic support for SZ and BP. A final validation step now separates diaMentis from FDA approval. This step consists of finalizing the conditions for obtaining ERG signals and selecting the most efficient mathematical and biostatistical analysis models through a clinical validation study with a representative sample of the US population.

Diseases with multiple co-factors, late diagnosis and irreversible damage to many lives

Among these diseases, two are irreversible, SZ and BP, while MDD can potentially be long-lasting and in some cases even be present throughout the patient’s life.

Because multiple cofactors coexist and overlap within these pathologies, the diagnosis is often made and maintained over very long periods of time. Therefore, people with SZ or BP typically wait between 5 and 7 years before receiving a clear and accurate diagnosis and adequate support for their treatment and medical follow-up.

The story goes on

These long delays, in which the disease continues to progress without being diagnosed, result in many people with SZ or BP losing the ability to lead a functioning life while diagnosed in the early stages of these diseases — that is, when the Warning symptoms appear by their appearance – they could be treated quickly and maintain a functional life.

Healthcare systems would also benefit from its use as SZ and BP’s annual medical, social and economic costs soar $155 billion and $213 billion in The United States ^3.4. These costs are also observed in Canada in relation to.

The retina is the only visible part of the human brain

Since the retina is connected to the central nervous system, analyzing the retinal signals allows us to highlight the presence of multiple biosignatures. Thanks to this new medical technology, a conclusive diagnosis can now be confirmed or invalidated by the clinician – general practitioner or psychiatrist – in less than 12 hours after examining the retinal signals, instead of waiting an average of 5 to 7 years due to the lack of diagnostic support tools, as is currently the case in mental health.

Appropriate treatment can be provided earlier in the disease course and follow-up of each patient’s treatment can be monitored by subsequent retinal signal studies.

Quote

“Our advancements and dialogue with the FDA motivate us to enrich this portfolio of supportive rapid diagnostic solutions for the benefit of every patient and their natural caregiver who struggle with mental illness on a daily basis. Being able to contribute in the near future Solving one of the most important mental health problems, namely the lack of rapid diagnosis in the early stages of the disease, will one day allow health systems around the world to benefit from a diagnostic tool, which is accessible to every doctor dealing with mental health problems. Our innovative technology could also be applied to other psychiatric and non-psychiatric indications with additional necessary capital and resources.” – Norman TremblayCo-founder and CEO, diaMentis

About diaMentis

Result of the work of Laval UniversitydiaMentis has a robust intellectual property for analyzing retinal signals with patents recognized in 156 countries. The company was awarded a breakthrough designation by the FDA, the world’s largest regulatory agency. diaMentis has 118 private and institutional shareholders Quebec and Canada. It has raised $32Mmainly from the private sector, for developing its technology to support rapid diagnosis for SZ, BP and MDD since its university spin-off in 2016. With a growing scientific literature supporting its initiatives, diaMentis currently has 31 employees from eight different nationalities holding 19 PhDs or master’s degrees and is conducting its validation study at 15 American and Canadian clinical sites, including Harvard Universitythe Feinstein Institute University of Rochesterthe University of Montreal, McGill University and the University of Toronto.

Accueil

SOURCE diaMentis

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/September2022/22/c9813.html